PMID- 35418272
OWN - NLM
STAT- MEDLINE
DCOM- 20220415
LR  - 20220716
IS  - 1526-2359 (Electronic)
IS  - 1073-2748 (Print)
IS  - 1073-2748 (Linking)
VI  - 29
DP  - 2022 Jan-Dec
TI  - Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death 
      Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase 
      III Trials.
PG  - 10732748221092924
LID - 10.1177/10732748221092924 [doi]
LID - 10732748221092924
AB  - Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) 
      inhibitors have been increasingly used in cancer therapy. The aim of this study 
      was conducted a meta-analysis to assess the efficacy and safety of PD-1/PD-L1 
      inhibitors in patients with unresectable hepatocellular carcinoma (uHCC). A total 
      of 1657 patients were included. The completed phase III trials with details data, 
      such as overall survival (OS), progression-free survival (PFS), objective 
      response rate (ORR), disease control rate (DCR), and adverse effects (AEs) were 
      included. The pooled hazard ratio (HR) of OS and PFS were .75 (95% CI: .61-.92) 
      and .74 (95% CI: .56-.97) with heterogeneity between PD-1/PD-L1 inhibitors groups 
      and control groups. Sensitivity analysis revealed IMbrave-150 could be the most 
      important factor of heterogeneity for OS, while CheckMate-459 was the main fact 
      of heterogeneity for PFS. In addition, the relative risk (RR) of ORR and DCR were 
      2.43 (95% CI: 1.80-3.26) and 1.26 (95% CI: 1.11-1.43) with low heterogeneity in 
      PD-1/PD-L1 inhibitors groups. The therapeutic effect of PD-1/PD-L1 inhibitors was 
      better in females, Asia without Japan, BCLC status C and infected hepatitis 
      groups. The RR of AEs from any cause and serious adverse events (SAEs) for 
      patients receiving PD-1/PD-L1 inhibitors were 1.03 (95% CI: .93-1.13) and 1.13 
      (95% CI: .89-1.44), respectively. Pruritus was the most common AEs reported in 
      10% of patients or more (RR = 1.69, 95% CI: 1.33-2.15). In conclusion, PD-L1 
      inhibitor combined with anti-VEGF antibody could improve the prognosis of 
      patients with uHCC. However, caution should be taken for AEs during patients 
      receiving PD-1/PD-L1 inhibitors.
FAU - Zeng, Linyan
AU  - Zeng L
AD  - Intensive Care Unit, The First Affiliated Hospital, 12377Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Su, Junwei
AU  - Su J
AD  - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National 
      Clinical Research Center for Infectious Diseases, Collaborative Innovation Center 
      for Diagnosis and Treatment of Infectious Diseases, The First Affiliated 
      Hospital, 12377Zhejiang University School of Medicine, Hangzhou, China.
FAU - Qiu, Wenqi
AU  - Qiu W
AD  - Department of Surgery, HKU-SZH & Faculty of Medicine, 25809The University of Hong 
      Kong, Hong Kong, China.
FAU - Jin, Xuehang
AU  - Jin X
AD  - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National 
      Clinical Research Center for Infectious Diseases, Collaborative Innovation Center 
      for Diagnosis and Treatment of Infectious Diseases, The First Affiliated 
      Hospital, 12377Zhejiang University School of Medicine, Hangzhou, China.
FAU - Qiu, Yunqing
AU  - Qiu Y
AD  - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National 
      Clinical Research Center for Infectious Diseases, Collaborative Innovation Center 
      for Diagnosis and Treatment of Infectious Diseases, The First Affiliated 
      Hospital, 12377Zhejiang University School of Medicine, Hangzhou, China.
FAU - Yu, Wei
AU  - Yu W
AUID- ORCID: 0000-0002-1174-596X
AD  - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National 
      Clinical Research Center for Infectious Diseases, Collaborative Innovation Center 
      for Diagnosis and Treatment of Infectious Diseases, The First Affiliated 
      Hospital, 12377Zhejiang University School of Medicine, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Cancer Control
JT  - Cancer control : journal of the Moffitt Cancer Center
JID - 9438457
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Ligands)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Apoptosis
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Clinical Trials, Phase III as Topic
MH  - Female
MH  - Humans
MH  - *Immune Checkpoint Inhibitors/adverse effects
MH  - Ligands
MH  - *Liver Neoplasms/drug therapy
MH  - Programmed Cell Death 1 Receptor
PMC - PMC9014721
OTO - NOTNLM
OT  - adverse effects
OT  - hepatocellular carcinoma
OT  - programmed cell death
OT  - programmed cell death ligand 1
OT  - survival
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2022/04/15 06:00
MHDA- 2022/04/16 06:00
PMCR- 2022/04/14
CRDT- 2022/04/14 05:17
PHST- 2022/04/14 05:17 [entrez]
PHST- 2022/04/15 06:00 [pubmed]
PHST- 2022/04/16 06:00 [medline]
PHST- 2022/04/14 00:00 [pmc-release]
AID - 10.1177_10732748221092924 [pii]
AID - 10.1177/10732748221092924 [doi]
PST - ppublish
SO  - Cancer Control. 2022 Jan-Dec;29:10732748221092924. doi: 
      10.1177/10732748221092924.